Literature DB >> 22728222

Antibody response to the central unglycosylated region of the respiratory syncytial virus attachment protein in mice.

Yoshihiko Murata1, Seana C Catherman.   

Abstract

We examined the humoral immune response to the unglycosylated central region of the respiratory syncytial virus (RSV) attachment (G) protein in mice following intranasal challenge at day 0 (primary) and day 21 (secondary) with subtype A (A2 strain) or B (B1 strain) RSV preparations. Our serological screening reagents included bacterially derived glutathione S-transferase (GST) fusion proteins, each bearing a portion of the RSV G central core (CC; residues 151-190), proximal central core (PCC; residues 151-172), and the distal central core (DCC; residues 173-190) and purified RSV G proteins from subtype A and B viruses. Convalescent sera collected on day 21 following primary RSV infection bore robust IgG response primarily against the homosubtypic RSV G DCC with relatively modest antigen affinity/avidity as demonstrated by brief incubation with 6M urea. In contrast, sera collected on day 42 following secondary homosubtypic RSV infection bore IgG titers of higher magnitudes and antigen affinity/avidity against the homosubtypic RSV G CC, PCC, and/or the DCC regions and full-length RSV G protein but not against the heterosubtypic RSV G protein or recombinant CC subdomains. In contrast, heterosubtypic secondary RSV infection elicits a broad array of IgG responses with titers of varying magnitudes to homo- and heterosubtypic RSV G CC regions as well as to purified F, Ga, and Gb proteins with the notable exception of minimal response to the RSV G DCC domain associated with the secondary RSV challenge. Our results have implications for RSV G-based serological assays as well as prophylactic immunotherapy and RSV vaccine development.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22728222      PMCID: PMC3401318          DOI: 10.1016/j.vaccine.2012.06.016

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  47 in total

1.  Evaluation of the antibody specificities of human convalescent-phase sera against the attachment (G) protein of human respiratory syncytial virus: influence of strain variation and carbohydrate side chains.

Authors:  C Palomo; P A Cane; J A Melero
Journal:  J Med Virol       Date:  2000-04       Impact factor: 2.327

2.  Methods for monitoring dynamics of pulmonary RSV replication by viral culture and by real-time reverse transcription-PCR in vivo: Detection of abortive viral replication.

Authors:  Marina S Boukhvalova; Kevin C Yim; Gregory A Prince; Jorge C G Blanco
Journal:  Curr Protoc Cell Biol       Date:  2010-03

3.  Prophylactic treatment with a G glycoprotein monoclonal antibody reduces pulmonary inflammation in respiratory syncytial virus (RSV)-challenged naive and formalin-inactivated RSV-immunized BALB/c mice.

Authors:  Gertrud U Radu; Hayat Caidi; Congrong Miao; Ralph A Tripp; Larry J Anderson; Lia M Haynes
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

4.  Gene expression differences in lungs of mice during secondary immune responses to respiratory syncytial virus infection.

Authors:  Annemieke Schuurhof; Louis Bont; Jeroen L A Pennings; Hennie M Hodemaekers; Piet W Wester; Annemarie Buisman; Lia C G H de Rond; Myra N Widjojoatmodjo; Willem Luytjes; Jan L L Kimpen; Riny Janssen
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

5.  Purification of respiratory syncytial virus F and G proteins.

Authors:  C Roder; T Krusat; K Reimers; H Werchau
Journal:  J Chromatogr B Biomed Sci Appl       Date:  2000-01-14

6.  Multiplex assay for detection of strain-specific antibodies against the two variable regions of the G protein of respiratory syncytial virus.

Authors:  Les P Jones; Hao-Qiang Zheng; Ruth A Karron; Teresa C T Peret; Cecelia Tsou; Larry J Anderson
Journal:  Clin Diagn Lab Immunol       Date:  2002-05

7.  Humoral response to the central unglycosylated region of the respiratory syncytial virus attachment protein.

Authors:  Yoshihiko Murata; Paula M Lightfoote; Jamie N Biear; Ann R Falsey; Edward E Walsh
Journal:  Vaccine       Date:  2010-07-23       Impact factor: 3.641

8.  Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein.

Authors:  J J Gorman; J L McKimm-Breschkin; R S Norton; K J Barnham
Journal:  J Biol Chem       Date:  2001-08-03       Impact factor: 5.157

9.  Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology.

Authors:  Matthew R Murawski; Lori W McGinnes; Robert W Finberg; Evelyn A Kurt-Jones; Michael J Massare; Gale Smith; Penny M Heaton; Armando E Fraire; Trudy G Morrison
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

10.  The respiratory syncytial virus G protein conserved domain induces a persistent and protective antibody response in rodents.

Authors:  Thien N Nguyen; Ultan F Power; Alain Robert; Jean-François Haeuw; Katia Helffer; Amadeo Perez; Miguel-Angel Asin; Nathalie Corvaia; Christine Libon
Journal:  PLoS One       Date:  2012-03-29       Impact factor: 3.240

View more
  6 in total

1.  Recombinant influenza virus expressing a fusion protein neutralizing epitope of respiratory syncytial virus (RSV) confers protection without vaccine-enhanced RSV disease.

Authors:  Yu-Na Lee; Hye Suk Hwang; Min-Chul Kim; Young-Tae Lee; Jong Seok Lee; Martin L Moore; Sang-Moo Kang
Journal:  Antiviral Res       Date:  2014-12-13       Impact factor: 5.970

2.  Preclinical evaluation of bacterially produced RSV-G protein vaccine: Strong protection against RSV challenge in cotton rat model.

Authors:  Sandra Fuentes; Laura Klenow; Hana Golding; Surender Khurana
Journal:  Sci Rep       Date:  2017-02-10       Impact factor: 4.379

3.  Universal vaccine against respiratory syncytial virus A and B subtypes.

Authors:  Jeong-Yoon Lee; Jun Chang
Journal:  PLoS One       Date:  2017-04-06       Impact factor: 3.240

4.  Nanoparticle vaccines encompassing the respiratory syncytial virus (RSV) G protein CX3C chemokine motif induce robust immunity protecting from challenge and disease.

Authors:  Patricia A Jorquera; Youngjoo Choi; Katie E Oakley; Thomas J Powell; James G Boyd; Naveen Palath; Lia M Haynes; Larry J Anderson; Ralph A Tripp
Journal:  PLoS One       Date:  2013-09-10       Impact factor: 3.240

5.  The Complexity of Antibody Responses Elicited against the Respiratory Syncytial Virus Glycoproteins in Hospitalized Children Younger than 2 Years.

Authors:  Alfonsina Trento; Rosa Rodríguez-Fernández; María I González-Sánchez; Felipe González-Martínez; Vicente Mas; Mónica Vázquez; Concepción Palomo; José A Melero
Journal:  Front Microbiol       Date:  2017-11-22       Impact factor: 5.640

6.  Rapid replacement of human respiratory syncytial virus A with the ON1 genotype having 72 nucleotide duplication in G gene.

Authors:  You-Jin Kim; Dae-Won Kim; Wan-Ji Lee; Mi-Ran Yun; Ho Yeon Lee; Han Saem Lee; Hee-Dong Jung; Kisoon Kim
Journal:  Infect Genet Evol       Date:  2014-05-10       Impact factor: 3.342

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.